Chitosan-based systems for the delivery of vaccine antigens

References

• Ogra PL, Faden H, Wellinger RC. Vaccination strategies for mucosal immune responses. Clin. Microbiol. Rev.14(2), 430–445 (2001).
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Amiji MM. Enhanced mucosal and systemic immune response with squalane oil containing multiple emulsions upon intranasal and oral administration in mice. J. Drug Target.16(4), 302–310 (2008).
   PubMed Web of Science ®Google Scholar
• Olesen OF, Lonnroth A, Mulligan B. Human vaccine research in the European Union. Vaccine27(5), 640–645 (2009).
   PubMed Web of Science ®Google Scholar
• Katz SL. Future vaccines and a global perspective. Lancet350(9093), 1767–1770 (1997).
   PubMed Web of Science ®Google Scholar
• Del Giudice G, Pizza M, Rappuoli R. Mucosal delivery of vaccines. Methods19(1), 148–155 (1999).
   PubMed Web of Science ®Google Scholar
• Holmgren J, Czerkinsky C. Mucosal immunity and vaccines. Nat. Med.11(4), S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Kiyono H, Fukuyama S. NALT- versus Peyer’s patch-mediated mucosal immunity. Nat. Rev. Immunol.4(9), 699–710 (2004).
   PubMed Web of Science ®Google Scholar
• Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat. Rev. Immunol.6(2), 148–158 (2006).
   PubMed Web of Science ®Google Scholar
• Reed SG, Bertholet S, Coler RN, Friede M. New horizons in adjuvants for vaccine development. Trends Immunol.30(1), 23–32 (2009).
   PubMed Web of Science ®Google Scholar
• Perrie Y, Mohammed AR, Kirby DJ, McNeil SE, Bramwell VW. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens. Int. J. Pharm.364(2), 272–280 (2008).
   PubMed Web of Science ®Google Scholar
• Saupe A, McBurney W, Rades T, Hook S. Immunostimulatory colloidal delivery systems for cancer vaccines. Expert Opin. Drug Deliv.3(3), 345–354 (2006).
   PubMed Web of Science ®Google Scholar
• Garcon N, Van Mechelen M, Wettendorff M. Development and evaluation of AS04, a novel and improved adjuvant system containing MPL and aluminium salt. In:Immunopotentiators in Modern Vaccines. Schinjs VEJC, O’Hagan DT (Eds.). Elsevier Academic Press, London, UK, 161–177 (2006).
   Google Scholar
• Lin X, Hudock H, Arumugham R, Loun B. Identification of particulates in vaccine formulations containing aluminum phosphate. Vaccine26(52), 6814–6817 (2008).
   PubMed Web of Science ®Google Scholar
• Miles AP, McClellan HA, Rausch KM et al. Montanide® ISA 720 vaccines: quality control of emulsions, stability of formulated antigens, and comparative immunogenicity of vaccine formulations. Vaccine23(19), 2530–2539 (2005).
   PubMed Web of Science ®Google Scholar
• Peter K, Men Y, Pantaleo G, Gander B, Corradin G. Induction of a cytotoxic T-cell response to HIV-1 proteins with short synthetic peptides and human compatible adjuvants. Vaccine19(30), 4121–4129 (2001).
   PubMed Web of Science ®Google Scholar
• de Bruijn I, Meyer I, Gerez L, Nauta J, Giezeman K, Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine26, 119–127 (2007).
   PubMed Web of Science ®Google Scholar
• Cavanagh DR, Remarque EJ, Sauerwein RW, Hermsen CC, Luty AJF. Influenza virosomes: a flu jab for malaria? Trends Parasitol.24(9), 382–385 (2008).
   PubMed Web of Science ®Google Scholar
• Li Q, Gao JQ, Qiu LY, Cui FD, Jin Y. Enhanced immune responses induced by vaccine using Sendai virosomes as carrier. Int. J. Pharm.329(1–2), 117–121 (2007).
   PubMed Web of Science ®Google Scholar
• Wilson-Welder JH, Torres MP, Kipper MJ, Mallapragada SK, Wannemuehler MJ, Narasimhan B. Vaccine adjuvants: current challenges and future approaches. J. Pharm. Sci.98(4), 1278–1316 (2009).
   PubMed Web of Science ®Google Scholar
• Liang MT, Davies NM, Blanchfield JT, Toth I. Particulate systems as adjuvants and carriers for peptide and protein antigens. Curr. Drug Deliv.3(4), 379–388 (2006).
   PubMedGoogle Scholar
• Cox E, Verdonck F, Vanrompay D, Goddeeris B. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa. Vet. Res.37(3), 511–539 (2006).
   PubMed Web of Science ®Google Scholar
• Trujillo-Vargas CM, Mayer KD, Bickert T et al. Vaccinations with T-helper type 1 directing adjuvants have different suppressive effects on the development of allergen-induced T-helper type 2 responses. Clin. Exp. Allergy.35(8), 1003–1013 (2005).
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Kwon GS, Samuel J. Biodegradable nanoparticle delivery of a Th2-biased peptide for induction of Th1 immune responses. J. Pharm. Pharmacol.58(6), 739–747 (2006).
   PubMed Web of Science ®Google Scholar
• Petrovsky N. Novel human polysaccharide adjuvants with dual Th1 and Th2 potentiating activity. Vaccine24(Suppl. 2), S2–26–29 (2006).
   Google Scholar
• Das G, Sheridan S, Janeway CA Jr. The source of early IFN-γ that plays a role in Th1 priming. J. Immunol.167(4), 2004–2010 (2001).
   PubMed Web of Science ®Google Scholar
• Morein B, Sundquist B, Hoglund S, Dalsgaard K, Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature308(5058), 457–460 (1984).
   PubMed Web of Science ®Google Scholar
• Pearse MJ, Drane D. ISCOMATRIX® adjuvant for antigen delivery. Adv. Drug Deliv. Rev.57(3), 465–474 (2005).
   PubMed Web of Science ®Google Scholar
• Wee JL, Scheerlinck JP, Snibson KJ et al. Pulmonary delivery of ISCOMATRIX influenza vaccine induces both systemic and mucosal immunity with antigen dose sparing. Mucosal Immunol.1(6), 489–496 (2008).
   PubMed Web of Science ®Google Scholar
• Jaafari MR, Badiee A, Khamesipour A et al. The role of CpG ODN in enhancement of immune response and protection in BALB/c mice immunized with recombinant major surface glycoprotein of Leishmania (rgp63) encapsulated in cationic liposome. Vaccine25(32), 6107–6117 (2007).
   PubMed Web of Science ®Google Scholar
• Yan W, Huang L. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int. J. Pharm.368(1–2), 56–62 (2009).
   PubMed Web of Science ®Google Scholar
• Yan W, Chen W, Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J. Control. Release130(1), 22–28 (2008).
   PubMed Web of Science ®Google Scholar
• He X, Jiang L, Wang F et al. Augmented humoral and cellular immune responses to hepatitis B DNA vaccine adsorbed onto cationic microparticles. J. Control. Release107(2), 357–372 (2005).
   PubMed Web of Science ®Google Scholar
• Zhao A, Rodgers VGJ. Using TEM to couple transient protein distribution and release for PLGA microparticles for potential use as vaccine delivery vehicles. J. Control. Release113(1), 15–22 (2006).
   PubMed Web of Science ®Google Scholar
• Estevan M, Gamazo C, Grilló MJ, Del Barrio GG, Blasco JM, Irache JM. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice. Vaccine24(19), 4179–4187 (2006).
   PubMed Web of Science ®Google Scholar
• Borges O, Borchard G, Verhoef JC, de Sousa A, Junginger HE. Preparation of coated nanoparticles for a new mucosal vaccine delivery system. Int. J. Pharm.299(1–2), 155–166 (2005).
   PubMed Web of Science ®Google Scholar
• Sayın B, Somavarapu S, Li XW et al. Mono-N-carboxymethyl chitosan (MCC) and N-trimethyl chitosan (TMC) nanoparticles for non-invasive vaccine delivery. Int. J. Pharm.363(1–2), 139–148 (2008).
   PubMed Web of Science ®Google Scholar
• O’Hagan DT, Singh M, Ulmer JB. Microparticle-based technologies for vaccines. Methods40(1), 10–19 (2006).
   PubMed Web of Science ®Google Scholar
• Fehr T, Skrastina D, Pumpens P, Zinkernagel RM. T cell-independent type I antibody response against B cell epitopes expressed repetitively on recombinant virus particles. Immunology95(16), 9477–9481 (1998).
   Google Scholar
• O’Hagan DT, Singh M. Microparticles as vaccine adjuvants and delivery systems. Expert Rev. Vaccines2(2), 269–283 (2003).
   PubMedGoogle Scholar
• Kipper MJ, Wilson JH, Wannemuehler MJ, Narasimhan B. Single dose vaccine based on biodegradable polyanhydride microspheres can modulate immune response mechanism. J. Biomed. Mater. Res. A.76(4), 798–810 (2006).
   PubMedGoogle Scholar
• Florindo HF, Pandit S, Goncalves LMD, Alpar HO, Almeida AJ.Streptococcus equi antigens adsorbed onto surface modified poly-ε-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine26(33), 4168–4177 (2008).
   PubMed Web of Science ®Google Scholar
• Alpar HO, Somavarapu S, Atuah KN, Bramwell VW. Biodegradable mucoadhesive particulates for nasal and pulmonary antigen and DNA delivery. Adv. Drug. Deliv. Rev.57, 411–430 (2005).
   PubMed Web of Science ®Google Scholar
• Singh M, Fang J, Kazzaz J et al. A modified process for preparing cationic polylactide-co-glycolide microparticles with adsorbed DNA. Int. J. Pharm.327(1–2), 1–5 (2006).
   PubMed Web of Science ®Google Scholar
• Gombotz WR, Wee SF. Protein release from alginate matrices Adv. Drug Deliv. Rev.31(3), 267–285 (1998).
   PubMed Web of Science ®Google Scholar
• Sayın B, Şenel S. Chitosan and its derivatives for mucosal immunization. In: Current Research and Developments on Chitin and Chitosan in Biomaterials Science (Volume 1). Jayakumar R, Prabaharan M (Eds). Research Signpost, Kerala, India, 145–165 (2008).
   Google Scholar
• Combadiére B, Mahe B. Particle-based vaccines for transcutaneous vaccination. Comp. Immunol. Microbiol. Infect. Dis.31(2–3), 293–315 (2008).
   PubMed Web of Science ®Google Scholar
• McGeary RP, Olive C, Toth I. Lipid and carbohydrate based adjuvant/carriers in immunology. J. Peptide Sci.9(7), 405–418 (2003).
   PubMed Web of Science ®Google Scholar
• Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J. Control. Release121(1–2), 3–9 (2007).
   PubMed Web of Science ®Google Scholar
• Peek LJ, Middaugh CR, Berkland C. Nanotechnology in vaccine delivery. Adv. Drug Deliv. Rev.60(8), 915–928 (2008).
   PubMed Web of Science ®Google Scholar
• Şenel S, Kaş HS, Squier CA. Application of chitosan in dental drug delivery and therapy. In: Chitosan Per os: From Dietary Supplement to Drug Carrier. Muzzarelli RAA (Ed.). Atec, Grottammare, Italy, 241–256 (2000).
   Google Scholar
• Şenel S, McClure SJ. Potential applications of chitosan in veterinary medicine. Adv. Drug Deliv. Rev.56(10), 1467–1480 (2004).
   PubMed Web of Science ®Google Scholar
• Şenel S, Kremer MJ, Kaş HS, Wertz PW, Hıncal AA, Squier CA. Effect of chitosan in enhancing drug delivery across buccal mucosa. In: Advances in Chitin Sciences (Volume 4). Peter MG, Muzzarelli RAA, Domard A (Eds). University of Potsdam, Germany, 254–258 (2000).
   Google Scholar
• Illum L, Farraj NF, Davis SS. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res.11(8), 1186–1189 (1994).
   PubMed Web of Science ®Google Scholar
• Thanou M, Verhoef JC, Junginger HE. Oral drug absorption enhancement by chitosan and its derivatives. Adv. Drug Deliv. Rev.52(2), 117–126 (2001).
   PubMed Web of Science ®Google Scholar
• Şenel S, Kremer MJ, Kaş S, Wertz PW, Hıncal AA, Squier CA. Enhancing effect of chitosan on peptide drug delivery across buccal mucosa. Biomaterials21(20), 2067–2071 (2000).
   PubMed Web of Science ®Google Scholar
• Berth G, Voigt A, Dautzenberg H, Donath E, Möhwald H. Polyelectrolyte complexes and layer-by-layer capsules from chitosan/chitosan sulfate. Biomacromolecules3(3), 579–590 (2002).
   PubMed Web of Science ®Google Scholar
• Sorlier P, Denuziere A, Viton C, Domard A. Relation between the degree of acetylation and the electrostatic properties of chitin and chitosan. Biomacromolecules2(3), 765–772 (2001).
   PubMed Web of Science ®Google Scholar
• Kang ML, Kang SG, Jiang HL et al. Chitosan microspheres containing Bordetella bronchiseptica antigens as novel vaccine against atrophic rhinitis in pigs. J. Microbiol. Biotechnol.18(6), 1179–1185 (2008).
   PubMed Web of Science ®Google Scholar
• Lai WF, Lin MC. Nucleic acid delivery with chitosan and its derivatives. J. Control. Release134(3), 158–168 (2009).
   PubMed Web of Science ®Google Scholar
• Wimer-Mackin S, Hinchcliffe M, Petrie CR et al. An intranasal vaccine targeting both the Bacillus anthracis toxin and bacterium provides protection against aerosol spore challenge in rabbits. Vaccine24(18), 3953–3963 (2006).
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine25(11), 2085–2094 (2007).
   PubMed Web of Science ®Google Scholar
• Issa MM, Köping-Höggard M, Artursson P. Chitosan and the mucosal delivery of biotechnology drugs. Drug Discov. Today2(1), 1–6 (2005).
   Google Scholar
• Kotze AF, Thanou M, Lueßen HL, de Boerd BG, Verhoef JC, Junginger HE. Effect of the degree of quaternization of N-trimethyl chitosan chloride on the permeability of intestinal epithelial cells (Caco-2). Eur. J. Pharm. Biopharm.47(3), 269–274 (1999).
   PubMed Web of Science ®Google Scholar
• Colo GD, Zambito Y, Burgalassi S, Nardini I, Saettone MF. Effect of chitosan and of N-carboxymethylchitosan on intraocular penetration of topically applied ofloxacin. Int. J. Pharm.273(1–2), 37–44 (2004).
   PubMed Web of Science ®Google Scholar
• Kean T, Roth S, Thanou MJ. Trimethylated chitosans as nonviral gene delivery vectors: cytotoxicity and transfection efficiency. J. Control. Release103(3), 643–653 (2005).
   PubMed Web of Science ®Google Scholar
• Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J. Control. Release100(1), 5–28 (2004).
   PubMed Web of Science ®Google Scholar
• Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW. Chitosan solution enhances the immunoadjuvant properties of GM-CSF. Vaccine25(52), 8673–8686 (2007).
   PubMed Web of Science ®Google Scholar
• Ghendon Y, Markushin S, Krivtsov G, Akopova I. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch. Virol.153(5), 831–837 (2008).
   PubMed Web of Science ®Google Scholar
• Coeshott CM, Smithson SL, Verderber Eet al. Pluronic F127-based systemic vaccine delivery systems. Vaccine22(19), 2396–2405 (2004).
   PubMed Web of Science ®Google Scholar
• Kang ML, Jiang HL, Kang SG et al. Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin. Vaccine25(23), 4602–4610 (2007).
   PubMed Web of Science ®Google Scholar
• Gordon S, Saupe A, McBurney W, Rades T, Hook S. Comparison of chitosan nanoparticles and chitosan hydrogels for vaccine delivery. J. Pharm. Pharmacol.60(12), 1591–600 (2008).
   PubMed Web of Science ®Google Scholar
• Lee JW, Park JH, Robinson JR. Bioadhesive-based dosage forms: the next generation. J. Pharm. Sci.89(7), 850–66 (2000).
   PubMed Web of Science ®Google Scholar
• Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS. Chitosan as a novel nasal delivery system for vaccines. Adv. Drug Deliv. Rev.51(1–3), 81–96 (2001).
   PubMed Web of Science ®Google Scholar
• Klas SD, Petrie CR, Warwood SJ et al. A single immunization with a dry powder anthrax vaccine protects rabbits against lethal aerosol challenge. Vaccine26(43), 5494–5502 (2008).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Giuliani MM, Verhoef JC, Rappuoli R, Junginger HE, Giudice GD. The concomitant use of the LTK63 mucosal adjuvant and of chitosan-based delivery system enhances the immunogenicity and efficacy of intranasally administered vaccines. Vaccine21(25–26), 3837–3844 (2003).
   PubMed Web of Science ®Google Scholar
• Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. Comparative immunomodulatory properties of a chitosan–MDP adjuvant combination following intranasal or intramuscular immunisation. Vaccine23(16), 1923–1930 (2005).
   PubMed Web of Science ®Google Scholar
• Borges O, Cordeiro-da-Silva A, Tavares J et al. Immune response by nasal delivery of hepatitis B surface antigen and codelivery of a CpG ODN in alginate coated chitosan nanoparticles. Eur. J. Pharm. Biopharm.69(2), 405–416 (2008).
   PubMed Web of Science ®Google Scholar
• Davies OR, Head L, Armitage D et al. Surface modification of microspheres with steric stabilizing and cationic polymers for gene delivery. Langmuir24(14), 7138–7146 (2008).
   PubMed Web of Science ®Google Scholar
• Csaba N, Garcia-Fuentes M, Alonso MJ. Nanoparticles for nasal vaccination. Adv. Drug Deliv. Rev.61(2), 140–157 (2009).
   PubMed Web of Science ®Google Scholar
• Jaganathan KS, Vyas SP. Strong systemic and mucosal immune responses to surface-modified PLGA microspheres containing recombinant hepatitis B antigen administered intranasally. Vaccine24(19), 4201–4211 (2006).
   PubMed Web of Science ®Google Scholar
• Amidi M, Romeijn SG, Verhoef JCet al.N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model. Vaccine25(1), 144–153 (2007).
   PubMed Web of Science ®Google Scholar
• Amidi M, Pellikaan HC, Hirschberg H et al. Diphtheria toxoid-containing microparticulate powder formulations for pulmonary vaccination: preparation, characterization and evaluation in guinea pigs. Vaccine25(37–38), 6818–6829 (2007).
   PubMed Web of Science ®Google Scholar
• Jiang HL, Kang ML, Quan JS et al. The potential of mannosylated chitosan microspheres to target macrophage mannose receptors in an adjuvant-delivery system for intranasal immunization. Biomaterials29(12), 1931–1939 (2008).
   PubMed Web of Science ®Google Scholar
• Svirshchevskaya EV, Alekseeva LG, Reshetov PD et al. Mucoadjuvant properties of lipo- and glycoconjugated derivatives of oligochitosans. Eur. J. Med. Chem.44(5), 2030–2037 (2009).
   PubMed Web of Science ®Google Scholar
• Jiang L, Qian F, He X et al. Novel chitosan derivative nanoparticles enhance the immunogenicity of a DNA vaccine encoding hepatitis B virus core antigen in mice. J. Gene Med.9(4), 253–264 (2007).
   PubMed Web of Science ®Google Scholar
• Read RC, Naylor SC, Potter CW et al. Effective nasal influenza vaccine delivery using chitosan. Vaccine23(35), 4367–4374 (2005).
   PubMed Web of Science ®Google Scholar
• McNeela EA, Jabbal-Gill I, Illum L et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine22(8), 909–914 (2004).
   PubMed Web of Science ®Google Scholar
• Huo Z, Sinha R, McNeela EA et al. Induction of protective serum meningococcal bactericidal and diphtheria-neutralizing antibodies and mucosal immunoglobulin a in volunteers by nasal insufflations of the Neisseria meningitidis serogroup C polysaccharide CRM197 conjugate vaccine mixed with chitosan. Infect. Immun.73(12), 8256–8265 (2005).
   PubMed Web of Science ®Google Scholar
• Maxwell S, Şenel S, McClure S. Mucosal vaccination of sheep with heliotrine antigen. Presented at: 13th International Pharmaceutical Technology Symposium. Ankara, Turkey, 10–13 September 2006.
   Google Scholar
• Maxwell S, Şenel S, McClure S. Chitosan for delivery of mucosal vaccines in ruminants. Presented at: 33rd Annual Meeting and Exposition of the Controlled Release Society. Vienna, Austria, 18–22 July 2006.
   Google Scholar
• Çokçalişkan C, Gürsoy RN, Günbeyaz M et al. Chitosan for mucosal immunization against the foot and mouth disease. Presented at: 35th Annual Meeting and Exposition of the Controlled Release Society. New York, USA, 12–16 July 2008.
   Google Scholar
• Gogev S, de Fays K, Versali MF, Gautier S, Thiry E. Glycol chitosan improves the efficacy of intranasally administrated replication defective human adenovirus type 5 expressing glycoprotein D of bovine herpesvirus 1. Vaccine22(15–16), 1946–1953 (2004).
   PubMed Web of Science ®Google Scholar
• Peluso G, Petillo O, Ranieri M et al. Chitosan-mediated stimulation of macrophage function. Biomaterials15(15), 1215–1220 (1994).
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nishimura S, Nishi N, Saiki I, Tokura S, Azuma I. Immunological activity of chitin and its derivatives. Vaccine2(1), 93–99 (1984).
   PubMedGoogle Scholar
• Nagamoto T, Hattori Y, Takayama K, Maitani Y. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res.21(4), 671–674 (2004).
   PubMed Web of Science ®Google Scholar
• Nishimura K, Nishimura S, Nishi N et al. Adjuvant activity of chitin derivatives in mice and guinea-pigs. Vaccine3(5), 379–384 (1985).
   PubMed Web of Science ®Google Scholar
• Foged C, Brodin B, Frokjaer S, Sundblad A. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm.298(2), 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Porporatto C, Bianco ID, Correa SG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukoc. Biol.78(1), 62–69 (2005).
   PubMed Web of Science ®Google Scholar
• McNeela EA, O’Connor D, Jabbal-Gill I et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine19(9–10), 1188–1198 (2001).
   Web of Science ®Google Scholar
• Davis SS. The use of soluble polymers and polymer microparticles to provide improved vaccine responses after parenteral and mucosal delivery. Vaccine24(2), S2–7–10 (2006).
   Web of Science ®Google Scholar
• Kang ML, Kang SG, Jiang HL et al.In vivo induction of mucosal immune responses by intranasal administration of chitosan microspheres containing Bordetella bronchiseptica DNT. Eur. J. Pharm. Biopharm.63(2), 215–220 (2006).
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang X, Kang Y et al. Interleukin-15 enhance DNA vaccine elicited mucosal and systemic immunity against foot and mouth disease virus. Vaccine26(40), 5135–5144 (2008).
   PubMed Web of Science ®Google Scholar
• Khatri K, Goyal AK, Gupta PN, Mishra N, Mehta A, Vyas SP. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine26(18), 2225–2233 (2008).
   PubMed Web of Science ®Google Scholar
• Khatri K, Goyal AK, Gupta PN, Mishra N, Vyas SP. Plasmid DNA loaded chitosan nanoparticles for nasal mucosal immunization against hepatitis B. Int. J. Pharm.354(1–2), 235–241 (2008).
   PubMed Web of Science ®Google Scholar
• Zhou X, Liu B, Yu X et al. Enhance immune response to DNA vaccine based on a novel multicomponent supramolecular assembly. Biomaterials28(31), 4684–4692 (2007).
   PubMed Web of Science ®Google Scholar
• Borges O, Tavares J, de Sousa A, Borchard G, Junginger HE, Cordeiro-da-Silva A. Evaluation of the immune response following a short oral vaccination schedule with hepatitis B antigen encapsulated into alginate-coated chitosan nanoparticles. Eur. J. Pharm. Sci.32(4–5), 278–290 (2007).
   PubMed Web of Science ®Google Scholar
• Yuan X, Yang X, Cai D et al. Intranasal immunization with chitosan/pCETP nanoparticles inhibits atherosclerosis in a rabbit model of atherosclerosis. Vaccine26(29–30), 3727–3734 (2008).
   PubMed Web of Science ®Google Scholar
• Garmise RJ, Staats HF, Hickey AJ. Novel dry powder preparations of whole inactivated influenza virus for nasal vaccination. AAPS Pharm. Sci. Tech.8(4), E81–E89 (2007).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Morandi M, Giuliani MM et al. Modulation of immune response to group C meningococcal conjugate vaccine given intranasally to mice together with the LTK63 mucosal adjuvant and the trimethyl chitosan delivery system. J. Infect. Dis.189(5), 828–832 (2004).
   PubMed Web of Science ®Google Scholar
• Baudner BC, Verhoef JC, Giuliani MM et al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J. Drug Target.13(8–9), 489–498 (2005).
   PubMed Web of Science ®Google Scholar
• Ahire VJ, Sawant KK, Doshi JB, Ravetkar SD. Chitosan microparticles as oral delivery system for tetanus toxoid. Drug Dev. Ind. Pharm.33(10), 1112–1124 (2007).
   PubMed Web of Science ®Google Scholar
• Vila A, Sánchez A, Janes K et al. Low molecular weight chitosan nanoparticles as new carriers for nasal vaccine delivery in mice. Eur. J. Pharm. Biopharm.57(1), 123–131 (2004).
   PubMed Web of Science ®Google Scholar
• Ravichandran E, Al-Saleem FH, Ancharski DM et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect. Immun.75(6), 3043–3054 (2007).
   PubMed Web of Science ®Google Scholar
• Xu W, Shen Y, Jiang Z, Wang Y, Chu Y, Xiong S. Intranasal delivery of chitosan–DNA vaccine generates mucosal SIgA and anti-CVB3 protection. Vaccine22(27–28), 3603–3612 (2004).
   PubMed Web of Science ®Google Scholar
• Xie Y, Zhou NJ, Gong YF et al. The immune response induced by H. pylori vaccine with chitosan as adjuvant and its relation to immune protection. World J. Gastroenterol.13(10), 1547–1553 (2007).
   PubMed Web of Science ®Google Scholar
• Chen F, Zhang ZR, Yuan F, Qin X, Wang M, Huang Y. In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery. Int. J. Pharm.349(1–2), 226–233 (2008).
   PubMed Web of Science ®Google Scholar
• Jain S, Sharma KR, Vyas SP. Chitosan nanoparticles encapsulated vesicular systems for oral immunization: preparation, in vitro and in vivo characterization. J. Pharm. Pharmacol.58(3), 303–310 (2006).
   PubMed Web of Science ®Google Scholar
• Hori M, Onishi H, Machida Y. Evaluation of Eudragit-coated chitosan microparticles as an oral immune delivery system. Int. J. Pharm.297(1–2), 223–234 (2005).
   PubMed Web of Science ®Google Scholar
• Shahiwala A, Vyas TK, Amiji MM. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat. Drug Deliv. Formul.1(1), 1–9 (2007).
   PubMedGoogle Scholar